Abiopharma

New Form 8-K - Aquestive Therapeutics, Inc. Filed: 2025-09-08 AccNo: 0001398733-25-000018 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

New Form 8-K - Moleculin Biotech, Inc. Filed: 2025-09-08 AccNo: 0001437749-25-028528 Size: 211 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Evolus - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Two New Publications from the Independent THERMAC Trial Featuring IceCures ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

CorMedix Announces Strategic Minority Investment in Talphera

Star Equity Holdings, Inc. RPO Subsidiary Rebrands to Hudson Talent Solutions

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton

New Form 8-K - Microbot Medical Inc. Filed: 2025-09-08 AccNo: 0001641172-25-026815 Size: 237 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits